Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Immutep Licenses IMP731 to GSK

By Drug Discovery Trends Editor | January 6, 2011

Immutep S.A. announced the execution of a licence agreement granting GSK exclusive worldwide rights to ImmuTune IMP731 and any other antibodies that deplete LAG-3 positive cells. IMP731 has demonstrated potency at low doses in preclinical models of T-cell mediated inflammation and could represent a new therapeutic approach to the treatment of autoimmune disease.
 
Under the terms of the agreement, GSK will assume all development responsibility and associated costs for IMP731. Immutep will receive an upfront payment and milestones of up to $100 million and is eligible for single-digit, tiered royalties if all objectives are achieved.
 
“We are very pleased to hand over the development of IMP731 to GSK, with its commitment to bringing breakthrough therapies to patients,” said John Hawken, CEO. “For Immutep, the value created through this transaction will enable us to focus our resources on advancing our oncology assets, IMP321 and IMP701. IMP321 is ready for a Phase 2b/3 trial in the chemo-immunotherapy of first-line metastatic cancer.”
 
IMP731 is a cytotoxic antibody that depletes activated T-cells. Chronically activated T-cells are a major component in many autoimmune diseases. LAG-3 (Lymphocyte Activation Gene-3) is a marker for activated long-lived effector-memory T-cells. Deleting activated pathogenic T-cells rather than simply blocking one of their functions (for example production of TNF-a, IL-6, IL-23) is a new therapeutic approach.
 
In addition, selective depletion of these pathogenic LAG-3+ T-cells will lead to targeted immunosuppression (i.e. only a subset of activated T-cells will be suppressed, not all T-cells as with corticoids or cyclosporin). This very specific long-lived immunosuppression should lead to higher therapeutic indices compared to classical immunosuppressive agents, with a reduced risk of increased susceptibility to infectious agents, as the pool of resting LAG-3 negative T-cells will be left untouched.
 
Overall, such a targeted therapy, inducing long-term effects with a minimum number of injections is a promising approach in the many autoimmune diseases where self-antigens have activated T-cells, for example, rheumatoid arthritis and multiple sclerosis.

Date: January 6, 2010
Source: Immutep S.A. 


Filed Under: Drug Discovery

 

Related Articles Read More >

Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
Labcorp widens precision oncology toolkit, aims to speed drug-trial enrollment
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE